Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Curevac N.V. (CVAC)

Curevac N.V. (CVAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Analysts Predict Strong Growth for Cancer Vaccine Market: Key Biotech Stocks to Consider

Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – Back in 2022, Nature published...

BIOV.CN : 0.0650 (-13.33%)
BVAXF : 0.0525 (-9.48%)
BNTX : 112.35 (+4.14%)
CVAC : 2.80 (-1.06%)
VXRT : 0.7200 (-0.35%)
IBRX : 5.27 (-0.57%)
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM

CVAC : 2.80 (-1.06%)
GSK and CureVac to Restructure Collaboration into New Licensing Agreement

GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations

CVAC : 2.80 (-1.06%)
Why CureVac Stock Plunged Today

A German court temporarily suspended proceedings in CureVac's IP lawsuit against BioNTech.

PFE : 27.13 (-1.20%)
CVAC : 2.80 (-1.06%)
BNTX : 112.35 (+4.14%)
3 Stocks to Buy For the COVID Resurgence

The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting

MRNA : 50.31 (+0.06%)
NVAX : 9.26 (+0.87%)
PFE : 27.13 (-1.20%)
ALNY : 274.83 (+0.96%)
ABUS : 3.73 (-4.85%)
BNTX : 112.35 (+4.14%)
CVAC : 2.80 (-1.06%)
LGF-A : N/A (N/A)
Why Shares of CureVac Jumped This Week

The company, which focuses on mRNA therapies, began a phase 1 trial for its cancer vaccine candidate.

GSK : 36.06 (-1.64%)
CVAC : 2.80 (-1.06%)
Why CureVac Stock Leaped 12% Higher Today

The war on cancer advances with the German company's latest clinical development.

CVAC : 2.80 (-1.06%)
Pre-Market Brief: Stocks Mostly Lower As Recession Worries Outweigh Cooler Inflation Data

March S&P 500 futures (ESH23) are trending down -0.41% this morning after three major U.S. benchmark indices ended the regular session lower as weak economic data and hawkish comments from Federal Reserve...

ESH23 : 3,957.05s (-0.09%)
CVAC : 2.80 (-1.06%)
AA : 44.41 (-2.80%)
NTLA : 16.12 (+0.75%)
DFS : 175.00 (unch)
ZYME : 16.77 (+7.43%)
VNO : 44.77 (+2.75%)
Why CureVac's Shares Jumped on Tuesday

The stock rose for the third consecutive day.

CVAC : 2.80 (-1.06%)
Unusual Options Activity Booms for Novavax (NVAX) But Concerns Remain

Unsurprisingly, positive sentiment toward Novavax’s change of leadership bolstered unusual options activity for NVAX stock. Still, prospective investors need to tread very carefully.

NVAX : 9.26 (+0.87%)
HRMY : 34.91 (+1.81%)
TEVA : 17.42 (-0.46%)
PFE : 27.13 (-1.20%)
CVAC : 2.80 (-1.06%)

Barchart Exclusives

Is DraftKings Stock a Buy After 2024 Guidance Cut?
DraftKings stock took a hit after revising its fiscal year 2024 revenue and adjusted EBITDA forecasts downward. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar